2q37 区 COP9 信号体基因缺失与多发性骨髓瘤 IMiD 耐药相关
研究利用 522 例多发性骨髓瘤患者全基因组测序数据,分析新诊断、来那度胺耐药及来那度胺后泊马度胺耐药时间点,发现 2q37 区 COP9 信号体成员 COPS7B 和 COPS8 拷贝缺失在耐药状态中显著富集,且 50 例纵向样本中 IMiD 暴露者 16% 获得 2q37 缺失。
要点
- 2q37 拷贝缺失发生率:新诊断 5.5%、来那度胺耐药 10.0%、来那度胺后泊马度胺耐药 16.4%。
- 50 例纵向样本中,IMiD 暴露者 16% 获得 2q37 缺失,无 IMiD 暴露者未见。
- 2q37 区包含 COPS7B 和 COPS8,可能作为 IMiD 耐药的新标志物。
核心结论
- 2q37 区 COP9 信号体基因 COPS7B 和 COPS8 拷贝缺失与 IMiD 耐药相关,可能成为 IMiD 耐药的新标志物并具有临床实用性。
研究设计与样本
- 研究使用大型全基因组测序患者数据集(n=522 例),涵盖新诊断、来那度胺耐药和来那度胺后泊马度胺耐药时间点。
- 另用独立数据集(50 例患者)的纵向样本分析治疗过程中的 2q37 缺失获得。
主要发现
- 在新诊断、来那度胺耐药和来那度胺后泊马度胺耐药状态中,2q37 拷贝缺失发生率分别为 5.5%、10.0% 和 16.4%,呈显著富集。
- 当克隆分数高时,2q37 拷贝缺失可能对结局产生不良影响。
- 在 50 例纵向样本中,IMiD 暴露者 16% 获得 2q37 缺失,无 IMiD 暴露者未见获得。
- 基于已发表的 CRISPR/shRNA IMiD 耐药筛选可重复识别的基因靶点,未发现突变所致遗传破坏与 IMiD 耐药相关的证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The acquisition of a multidrug refractory state is a major cause of mortality in myeloma. Myeloma drugs that target the cereblon (CRBN) protein include widely used immunomodulatory drugs (IMiDs), and newer CRBN E3 ligase modulator drugs (CELMoDs), in clinical trials. CRBN genetic disruption causes resistance and poor outcomes with IMiDs. Here, we investigate alternative genomic associations of IMiD resistance, using large whole-genome sequencing patient datasets (n = 522 cases) at newly diagnosed, lenalidomide (LEN)-refractory and lenalidomide-then-pomalidomide (LEN-then-POM)-refractory timepoints. Selecting gene targets reproducibly identified by published CRISPR/shRNA IMiD resistance screens, we found little evidence of genetic disruption by mutation associated with IMiD resistance. However, we identified a chromosome region, 2q37, containing COP9 signalosome members COPS7B and COPS8, copy loss of which significantly enriches between newly diagnosed (incidence 5.5%), LEN-refractory (10.0%), and LEN-then-POM-refractory states (16.4%), and may adversely affect outcomes when clonal fraction is high. In a separate dataset (50 patients) with sequential samples taken throughout treatment, we identified acquisition of 2q37 loss in 16% cases with IMiD exposure, but none in cases without IMiD exposure. The COP9 signalosome is essential for maintenance of the CUL4-DDB1-CRBN E3 ubiquitin ligase. This region may represent a novel marker of IMiD resistance with clinical utility.
引用
- Gooding S, Ansari-Pour N, Kazeroun M, et al. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 2022. PMID: 35853156. doi:10.1182/blood.2022015909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。